Skip To Content
Fast Forward

Denver drops drug charges against ‘mushroom rabbi’ who promotes religious psychedelic use

Coloradans recently voted to legalize psilocybin, the substance that Ben Gorelick had been charged with intending to distribute

(JTA) — A Denver rabbi who promotes psychedelic use as part of spiritual practice will no longer face prosecution after Coloradans voted last month to legalize psilocybin, the chemical compound found in psychedelic mushrooms.

Denver’s district attorney’s office announced last week that it was dropping charges against Ben Gorelick, the founder of  Sacred Tribe, a multifaith community that integrates psilocybin use and ideas rooted in Jewish tradition. A spokesperson for the office told the Denver Post that the move was “in light of the voters’ decision” to pass Proposition 122, which makes growing and sharing psilocybin and other related substances legal for adults over 21 in Colorado.

Gorelick had been charged in February with possessing a controlled substance with intent to manufacture or distribute it, a felony that carried mandatory prison time, even though Denver voters had already chosen to decriminalize psilocybin’s use.

“It’s been a long year for the community, it’s been a long year for us, and we look forward to getting back to practicing our religion, which is what the whole point of this is,” Gorelick told the Denver Post this week.

The charges had sidelined Sacred Tribe’s central purpose, although the group continued to hold Shabbat dinners and other activities for its roughly 270 members, who do not have to be Jewish. Gorelick, who was ordained in 2019 as a rabbi by the Jewish Spiritual Leaders Institute, an online program, had sought publicity and funding to fight the charges on religious freedom grounds.

He argues that there is a longstanding tradition of psychedelic drug use within Judaism, which even other Jewish advocates of psychedelics as part of spiritual practice dispute. Those advocates told the Guardian last summer that Gorelick, who said he screened community members to make sure they sought psilocybin for religious use, had not been known to their tight-knit community before his arrest.

Jewish psychedelics advocates have become more organized in recent years. Rabbi Zac Kamenetz, who was ordained as by an Orthodox rabbi in Israel, founded a group called Shefa during the pandemic that aims to one day make chemically-assisted mystical encounters into a normative part of Jewish spirituality. Last year, the group held a first-ever Jewish psychedelics conference.

Long considered illicit in the United States, psychedelics have been the subject of intensifying research, including about their potential as a therapeutic tool for treating trauma. One of the groups promoting the research, the Multidisciplinary Association for Psychedelic Studies, was founded by a Jewish man who was inspired by a dream about surviving the Nazis to devote his life to promoting psychedelics as a cure for human ills and an insurance policy against another Holocaust.

“I’m one of the very few people who can say they’ve had a legal experience with psychedelics in this country,” Kamenetz said last year. “To be able to speak freely about it without the stigma — because it’s not just people talking about doing illegal things — it’s allowed people to start having a more open conversation about it. When there’s the opportunity to hear from someone who did this in a legal environment, people will listen more.”

This article originally appeared on

A message from our editor-in-chief Jodi Rudoren

We're building on 127 years of independent journalism to help you develop deeper connections to what it means to be Jewish today.

With so much at stake for the Jewish people right now — war, rising antisemitism, a high-stakes U.S. presidential election — American Jews depend on the Forward's perspective, integrity and courage.

—  Jodi Rudoren, Editor-in-Chief 

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.